Article

V-ATPase inhibitors and implication in cancer treatment

{ "0" : "Entrerríos s/n, Santiago de Compostela C.P. 15782, Spain" , "1" : "Unidad de Medicina Molecular - Fundación Pública Galega de Medicina Xenómica, Edificio de Consultas planta -2, Hospital Clinico Universitario C.P. 15706, Santiago de Compostela, Spain" , "3" : "V-ATPase inhibitors" , "4" : "Tumor metastasis" , "5" : "Tumor cell growth" , "6" : "Chemoresistance" , "7" : "V-ATPases" , "8" : "Concanamycin" , "9" : "Bafilomycin" , "10" : "Salicylihalamide" , "11" : "Archazolid" , "12" : "Indolyls"}
Cancer Treatment Reviews (Impact Factor: 6.47). 12/2009; 35(8):707-713. DOI: 10.1016/j.ctrv.2009.08.003

ABSTRACT Acidity is one of the main features of the tumors. The V-ATPase is the primary responsible for the control of tumor microenvironment by proton extrusion to the extracellular medium. The acid environment favors tissue damage, activation of destructive enzymes in the extracellular matrix, the acquisition of metastatic cell phenotypes as well as increasing the destructive capacity. The application of specific inhibitors of V-ATPases, can decrease the acidity of tumor and may allow the reduction of tumor metastasis, acting on the survival of tumor cells and prevent the phenomena of chemoresistance. Among the most important inhibitors can be distinguished benzolactone enamides (salicylihalamide), lobatamide A and B, apicularen, indolyls, oximidine, macrolactone archazolid, lobatamide C, and cruentaren. The latest generation of inhibitors includes NiK12192, FR202126, and PPI SB 242784. The purpose of this paper is to describe the latest advances in the field of V-ATPase inhibitors, describe further developments related to the classic inhibitors, and discuss new potential applications of these drugs in cancer treatment.

Download full-text

Full-text

Available from: Abel García-García, Jul 28, 2015
1 Follower
 · 
306 Views
  • Source
    • "Due to their particular nature, benzimidazole proton pump inhibitors deserve a detailed report and thus they will be dealt with in another review article in this issue by de Milito and coworkers. A more comprehensive list and further details on these and other compounds are available in some excellent reviews [131] [132] [133] [134] [135]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer cells show a metabolic shift that makes them overproduce protons; this has the potential to disturb the cellular acid-base homeostasis. However, these cells show cytoplasmic alkalinisation, increased acid extrusion and endosome-dependent drug resistance. Vacuolar type ATPases (V-ATPases), together with other transporters, are responsible to a great extent for these symptoms. These multi-subunit proton pumps are involved in the control of cytosolic pH and the generation of proton gradients (positive inside) across endocellular membrane systems like Golgi, endosomes or lysosomes. In addition, in tumours, they have been shown to play an important role in the acidification of the intercellular medium. This importance makes them an attractive target to control tumour cell proliferation. In the present review we present the major characteristics of this kind of proton pumps and we provide some recent insights on their in vivo regulation. Also, we review some of the consequences that V-ATPase inhibition carries for the tumour cell, such as cell cycle arrest or cell death, and provide a brief summary of the studies related to cancer made recently with commercially available inhibitors. In the light of recent knowledge on the regulation of this proton pump, some new approaches to impair V-ATPase function are also suggested.
    Current pharmaceutical design 02/2012; 18(10):1383-94. DOI:10.2174/138161212799504821 · 3.29 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The hormetic morphogen theory of curvature (Fosslien 2009) proposes that hormetic morphogen concentration gradients modulate the synthesis of adenosine triphosphate (ATP) by cells along the gradients (field cells) and thus regulate their proliferation and induce curvature such as vascular wall curvature; however, it is unclear whether such morphogen gradients can also determine the histological pattern of the walls. Here, I propose that the ATP gradients modulate export of H(+) by vacuolar H(+)-ATPase (V-ATPase) located on the surface of field cells and generate extracellular ion concentration gradients, ion currents and electrical fields along the paths of morphogen gradients. In vitro, electrical fields can induce directional migration and elongation of vascular cells and align the cells with their long axis perpendicular to electrical field vectors (Bai et al. 2004). I suggest that likewise, in vivo vascular transmural electrical fields induced by hormetic morphogen concentration gradients can modulate cell shape i.e. cell elongation and cell curvature, and determine cell orientation. Moreover, I suggest that the electrical fields can modulate bidirectional cell migration and cell sorting via dynamic hormetic galvanotaxis analogous to in vitro isoelectric focusing in proton gradients, thus, hormetic morphogen gradients can determine the curvature of vessel walls and their histological patterns.
    Dose-Response 01/2010; 8(4):518-26. DOI:10.2203/dose-response.10-009.Fosslien · 1.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Resistance to chemotherapy agents is the main reason for treatment failure in patients with cancer. Multidrug resistance (MDR) is the primary mechanism that leads to the acquisition of the multiresistant phenotype through the overexpression of drug efflux transporters such as the P-glycoprotein (Pgp), encoded by the MDR1 gene, at the plasma membrane. Other molecules that have been implicated in drug resistance include multidrug resistance-associated proteins, glutathione S-transferase-pi, and DNA topoisomerase II. These molecules, however, cannot fully explain MDR in oral squamous cell carcinoma. Vacuolar ATPase (V-ATPase), which is largely responsible for regulating acidity in the microenvironment of solid tumors (and hence interfering with the absorption of chemotherapy drugs), seems to be the most important molecule involved in MDR in such tumors. Specific V-ATPase inhibitors, thus, may be useful, not only as coadjuvants in antitumor treatments but also as a mechanism for controlling resistance to antitumor drugs.
    Cancer letters 04/2010; 295(2):135-43. DOI:10.1016/j.canlet.2010.03.019 · 5.02 Impact Factor
Show more